Christine Schirmer

Dr. Christine Schirmer

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2019 in Talanta
Verified
Journal Article
Closed access
CSChristine Schirmer
Christine Schirmer
JPJuliane Posseckardt
Juliane Posseckardt
MSMathias Schröder
Mathias Schröder
MGMarkus Gläser
Markus Gläser
SHSteffen Howitz
Steffen Howitz
MMMichael Mertig
Michael Mertig

1 October 2018 in Journal of Biotechnology
Verified
Journal Article
Closed access
CSChristine Schirmer
Christine Schirmer
JPJ. Posseckardt
J. Posseckardt
AKA. Kick
A. Kick
KRK. Rebatschek
K. Rebatschek
WFW. Fichtner
W. Fichtner
MMMichael Mertig
Michael Mertig

9 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
LMLorenzo Francesco Madeo
Lorenzo Francesco Madeo
CSChristine Schirmer
Christine Schirmer
Giuseppe CirilloGiuseppe Cirillo
Giuseppe Cirillo
AAAyah Nadir Asha
Ayah Nadir Asha
RGRasha Ghunaim
Rasha Ghunaim
MMMichael Mertig
Michael Mertig
A ZnO-Graphene oxide nanocomposite (Z-G) was prepared in order to exploit the biomedical features of each component in a single anticancer material. This was achieved by means of an environmentally friendly synthesis, taking place at a low temperature and without the involvement of toxic reagents. The product was physicochemically characterized. The ZnO-to-GO ratio was determined through thermogravimetric analysis, while scanning electron microscopy and transmission electron microscopy were used to provide insight into the morphology of the nanocomposite. Using energy-dispersive X-ray spectroscopy, it was possible to confirm that the graphene flakes were homogeneously coated with ZnO. The crystallite size of the ZnO nanoparticles in the new composite was determined using X-ray powder diffraction. The capacity of Z-G to enhance the toxicity of the anticancer drug Paclitaxel towards breast cancer cells was assessed via a cell viability study, showing the remarkable anticancer activity of the obtained system. Such results support the potential use of Z-G as an anticancer agent in combination with a common chemotherapeutic like Paclitaxel, leading to new chemotherapeutic formulations.